ASR Vermogensbeheer’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.75M Buy
12,421
+1,131
+10% +$247K 0.03% 355
2026
Q2
$2.2M Sell
11,290
-1,539
-12% -$319K 0.02% 351
2026
Q1
$2.88M Buy
12,829
+260
+2% +$64.8K 0.03% 322
2025
Q4
$3.03M Sell
12,569
-130
-1% -$33.2K 0.04% 312
2025
Q3
$3.48M Sell
12,699
-97
-0.8% -$26.5K 0.04% 301
2025
Q2
$3.3M Buy
12,796
+542
+4% +$129K 0.04% 299
2025
Q1
$2.74M Buy
+12,254
New +$2.86M 0.04% 297

Other funds holding RMD

ASR Vermogensbeheer's RMD Position: Q3 2026 in Review

ASR Vermogensbeheer increased its ResMed (RMD) stake by 10% in Q3 2026, buying an estimated $247K and bringing the position to 12,421 shares worth $2.75M. The position accounts for 0.03% of the portfolio, ranked #355.

ASR Vermogensbeheer first reported a position in RMD in Q1 2025 and has held it in 7 quarters since. The position peaked at $3.48M in Q3 2025. 878 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • ASR Vermogensbeheer held 12,421 shares of ResMed worth $2.75M as of Q3 2026.
  • ASR Vermogensbeheer bought 1,131 ResMed shares in Q3 2026, an estimated $247K.
  • ResMed made up 0.03% of ASR Vermogensbeheer's portfolio in Q3 2026, its #355 holding.
  • ASR Vermogensbeheer first reported a position in ResMed in Q1 2025 and has held it in 7 quarters since.
  • ASR Vermogensbeheer's ResMed position peaked at $3.48M in Q3 2025.
  • 878 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on ASR Vermogensbeheer's 13F filing for Q3 2026, filed 16 Oct 2026.